{"nctId":"NCT00754845","briefTitle":"Letrozole in Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy","startDateStruct":{"date":"2004-11-23","type":"ACTUAL"},"conditions":["Breast Cancer"],"count":1918,"armGroups":[{"label":"Letrozole","type":"EXPERIMENTAL","interventionNames":["Drug: letrozole"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: placebo"]}],"interventions":[{"name":"letrozole","otherNames":["femara"]},{"name":"placebo","otherNames":["sugar pill"]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Previously diagnosed with primary breast cancer\n* Must have received 4½ - 6 years of aromatase inhibitor therapy (e.g., letrozole, anastrozole, or exemestane), either as initial therapy or after prior tamoxifen citrate, including treatment received as part of clinical trial CAN-NCIC-MA17\n\n  * Completed aromatase inhibitor therapy ≤ 2 years ago\n* No metastatic or recurrent disease, contralateral breast cancer, or ductal carcinoma in situ in either breast, as determined by the following:\n\n  * Clinical examination of the breast area, axillae, and neck within the past 60 days\n  * Mammogram within the past 12 months\\*\n  * Chest x-ray within the past 60 days\n  * Bone scan, if alkaline phosphatase \\> 2 times normal and/or there are symptoms of metastatic disease AND confirmatory x-ray, if bone scan results are questionable, within the past 60 days\n  * Abdominal ultrasound, liver scan, or CT scan of the abdomen within the past 60 days, if ALT, AST, or alkaline phosphatase \\> 2 times normal NOTE: \\*A baseline mammogram is not required for patients who have undergone bilateral complete mastectomy\n* Hormone-receptor status:\n\n  * Estrogen receptor positive (ER+) and/or progesterone receptor positive (PR+) primary tumor at the time of diagnosis, defined as a tumor receptor content of \\> 10 fmol/mg protein or receptor positive by immunocytochemical assay (for patients not previously enrolled on clinical trial CAN-NCIC-MA17)\n  * ER+ and/or PR+ primary tumor OR hormone receptor status of primary tumor unknown (for patients previously enrolled on clinical trial CAN-NCIC-MA17)\n\nPATIENT CHARACTERISTICS:\n\n* Menopausal status not specified\n* ECOG performance status 0-2\n* Life expectancy ≥ 5 years\n* WBC \\> 3.0 x 10\\^9/L OR granulocyte count (polymorphs + bands) ≥ 1.5 times 10\\^9/L\n* Platelet count \\> 100 x 10\\^9/L\n* AST and/or ALT \\< 2 times upper limit of normal (ULN)\\*\n* Alkaline phosphatase \\< 2 times ULN\\*\n* Able (i.e. sufficiently fluent) and willing to complete quality-of-life questionnaires in either English or French (NCIC CTG participating centers)\n\n  * Inability to complete questionnaires due to illiteracy in English or French, loss of sight, or other equivalent reason allowed\n* Accessible for treatment and follow-up\n* No other prior or concurrent malignancy except adequately treated, superficial squamous cell or basal cell skin cancer, carcinoma in situ of the cervix, or other cancer treated \\> 5 years ago that is presumed cured NOTE: \\*Elevated levels allowed provided imaging examinations have ruled out metastatic disease\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* No concurrent selective estrogen receptor modulator (e.g., raloxifene, idoxifene)\n* No other concurrent anticancer therapy","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"0 Years","maximumAge":"120 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Disease-free Survival (DFS)","description":"It is defined as the months from the day of randomization to the earliest date when a recurrence of the primary disease (recurrence in the breast, chest wall and nodal sites or the development of metastatic disease) or a contralateral breast cancer was observed. Subjects who died without recurrence of the primary disease or the development of the contralateral breast cancer were censored at their death date. If a patient has not recurred, developed a contralateral breast cancer, or died, disease-free survival was censored on the date of the last day the patient was known to be alive. Probability of disease free survival at 5 years is estimated and reported.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.95","spread":null},{"groupId":"OG001","value":"0.91","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Contralateral Breast Cancer","description":"The annual incidence rate was estimated based on the time to the development of contralateral breast cancer, which was calculated in months from the day of randomization to the diagnosis date of contralateral breast cancer for subjects who had developed the contralateral breast cancer, to the time of death for the patient who died, or to the last day the patient was known alive for subjects without contralateral breast cancer","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":null},{"groupId":"OG001","value":"4.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"For subjects who died, overall survival was calculated in months from the day of randomization to the date of death. Otherwise, survival was censored at the last day the patient was known to be alive. Probability of overall survival at 5 years is estimated and reported.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.93","spread":null},{"groupId":"OG001","value":"0.94","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Role Function- Physical Scale on SF(Short Form)-36 Health Survey","description":"Difference between post baseline scores and baseline score of role function-physical scale on SF-36 Health Survey (scale range between 0 and 100 with higher score indicating better quality of life).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.74","spread":"1.09"},{"groupId":"OG001","value":"-6.28","spread":"1.08"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":15,"n":959},"commonTop":["Arthralgia","Hot flashes/ flushes","Fatigue","Arthritis","Insomnia"]}}}